Mylan Laboratories Limited — Sitagliptin Exporter Profile
Indian Pharmaceutical Exporter · #3 for Sitagliptin · $7.0M export value · DGFT Verified
Mylan Laboratories Limited is the #3 Indian exporter of Sitagliptin with $7.0M in export value and 233 verified shipments. Mylan Laboratories Limited holds a 9.2% market share in Sitagliptin exports across 10 countries. The company exports 91 pharmaceutical products worth $634.8M across 26 therapeutic categories.
Mylan Laboratories Limited — Sitagliptin Export Profile: Buyers & Destinations
Where Does Mylan Laboratories Limited Export Sitagliptin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NETHERLANDS | $2.0M | 107 | 42.7% |
| FRANCE | $1.0M | 25 | 22.1% |
| MALTA | $913.5K | 46 | 19.7% |
| ITALY | $408.7K | 17 | 8.8% |
| SPAIN | $136.3K | 17 | 2.9% |
| GERMANY | $121.7K | 7 | 2.6% |
| THAILAND | $33.0K | 1 | 0.7% |
| UNITED KINGDOM | $20.7K | 1 | 0.4% |
| MEXICO | $407 | 9 | 0.0% |
| HUNGARY | $0 | 3 | 0.0% |
Mylan Laboratories Limited exports Sitagliptin to 10 countries. The largest destination is NETHERLANDS accounting for 42.7% of Mylan Laboratories Limited's Sitagliptin shipments, followed by FRANCE (22.1%) and MALTA (19.7%). These destinations reflect Mylan Laboratories Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Sitagliptin from Mylan Laboratories Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MYLAN IRELAND C/O ALLOGA RDC, | NETHERLANDS | $1.2M | 57 |
| XXLANXXRELXXD LXXITEXX NEXXNHAXXCOUXX MXXAHIXX RO | FRANCE | $759.0K | 36 |
| CSP MYLAN SAS AT CSP LABO 274 | FRANCE | $444.6K | 10 |
| M/S. CSP MYLAN SAS AT CSP LABO 2744 | MALTA | $250.0K | 5 |
| M/S. ALLOGA WAREHOUSE, | MALTA | $241.0K | 17 |
| MYLAN ITALIA S.R.L., | ITALY | $236.1K | 11 |
| VIATRIS PHARMACEUTICALS SL, | SPAIN | $207.2K | 16 |
| M/S. MYLAN IRELAND C/O ALLOGA RDC, | NETHERLANDS | $163.3K | 10 |
| M/S. ALLOGA UK, | MALTA | $157.4K | 4 |
| M/S. PHARMLOG, | MALTA | $123.1K | 5 |
Mylan Laboratories Limited supplies Sitagliptin to 35 buyers globally. The largest buyer is MYLAN IRELAND C/O ALLOGA RDC, (NETHERLANDS), followed by XXLANXXRELXXD LXXITEXX NEXXNHAXXCOUXX MXXAHIXX RO (FRANCE) and CSP MYLAN SAS AT CSP LABO 274 (FRANCE). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Sitagliptin Export Value and How Much Does Mylan Laboratories Limited Contribute?
India exported $46.1M worth of Sitagliptin through 5,364 shipments from 309 suppliers to 121 countries, serving 575 buyers globally. Mylan Laboratories Limited contributes $7.0M to this total, accounting for 9.2% of India's Sitagliptin exports. Mylan Laboratories Limited ships Sitagliptin to 10 countries through 35 buyers.
What Is the Average Shipment Value for Mylan Laboratories Limited's Sitagliptin Exports?
Mylan Laboratories Limited's average Sitagliptin shipment value is $30.0K per consignment, based on 233 shipments totaling $7.0M. The largest destination is NETHERLANDS (42.7% of Mylan Laboratories Limited's Sitagliptin exports).
How Does Mylan Laboratories Limited Compare to Other Indian Sitagliptin Exporters?
Mylan Laboratories Limited ranks #3 among 309 Indian Sitagliptin exporters with a 9.2% market share. The top 3 exporters are DR.REDDY'S LABORATORIES LTD ($7.7M), MYLAN LABORATORIES LIMITED ($7.0M), SANDOZ PRIVATE LIMITED ($6.5M). Mylan Laboratories Limited processed 233 shipments to 10 destination countries.
What Sitagliptin Formulations Does Mylan Laboratories Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| HARMLESS MEDICINES, SITAGLIPTIN MYLAN 10 | $626.0K | 19 |
| SITAGLIPTIN MYLAN 100 MG 28 BL TAB PACKS | $313.6K | 12 |
| SITAGLIPTINE VIATRIS 100 MG 28BL TAB PAC | $213.9K | 5 |
| SITAGLIPTIN TAB 100 MG 28 BL FR VIA PACK | $200.0K | 4 |
| HARMLESS MEDICINES, SITAGLIPTINA MYLAN 1 | $189.4K | 4 |
| SITAGLIPTINE VIATRIS 50 MG 28BL TAB | $167.7K | 4 |
| SITAGLIPTINE VIATRIS 100 MG 28 BL TAB PA | $150.0K | 3 |
| SITAGLIPTIN TAB 50MG 28BL IT MY | $101.6K | 3 |
| SITAGLIPTIN TAB 100 MG 28 BL UK MY PACKS | $100.0K | 2 |
| HARMLESS MEDICINES, SITAGLIPTINE VIATRIS | $100.0K | 2 |
Mylan Laboratories Limited exports 128 distinct Sitagliptin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is HARMLESS MEDICINES, SITAGLIPTIN MYLAN 10 with 19 shipments worth $626.0K.
How Does Mylan Laboratories Limited Compare to Nearest Sitagliptin Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | DR.REDDY'S LABORATORIES LTD | $7.7M | 243 | 8 | $31.9K |
| 3 | MYLAN LABORATORIES LIMITED ★ | $7.0M | 233 | 10 | $30.0K |
| 2 | SANDOZ PRIVATE LIMITED | $6.5M | 129 | 6 | $50.0K |
| 7 | AUROBINDO PHARMA LTD | $4.3M | 216 | 4 | $20.1K |
Mylan Laboratories Limited ranks #3 among 309 Indian Sitagliptin exporters. Average shipment value of $30.0K compared to the market average of $149.3K. The closest competitors by value are DR.REDDY'S LABORATORIES LTD and SANDOZ PRIVATE LIMITED.
Which Indian Ports Ship Sitagliptin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 772 | 14.4% |
| DELHI AIR CARGO ACC (INDEL4) | 739 | 13.8% |
| SAHAR AIR | 735 | 13.7% |
| DELHI AIR | 513 | 9.6% |
| NHAVA SHEVA SEA (INNSA1) | 217 | 4.0% |
| HYDERABAD AIR | 213 | 4.0% |
| Bombay Air | 196 | 3.7% |
| HYDERABAD ACC (INHYD4) | 191 | 3.6% |
Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Sitagliptin Exports
Mylan's export operations are influenced by a complex geopolitical landscape. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. Major shipping lines have implemented 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, directly impacting the cost structure for Indian pharmaceutical exporters like Mylan. Additionally, diversions around the Cape of Good Hope have further elongated delivery schedules, posing challenges to time-sensitive pharmaceutical shipments.
In the United States, the imposition of tariffs on pharmaceutical imports has prompted Indian companies to reassess their market strategies. While generics have largely remained exempt, the potential for future tariff expansions necessitates vigilance. Mylan, along with other Indian exporters, is exploring market diversification to mitigate reliance on the U.S. market. The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a strategic avenue for expansion. The FTA eliminates tariffs on approximately 97% of EU tariff lines, including pharmaceuticals, thereby enhancing market access for Indian exporters. This agreement is expected to significantly boost India's pharmaceutical exports to Europe, providing a counterbalance to uncertainties in the U.S. market.
Mylan Laboratories Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains paramount for Mylan. The FDA's warning letter and import alert in December 2024 concerning the Indore facility underscore the critical importance of stringent quality control measures. The cited violations, including subpar quality control and improper management of manufacturing defects, have necessitated comprehensive corrective actions. Mylan's proactive response aims to restore compliance and reinforce its commitment to quality assurance.
The evolving regulatory environment, particularly in the European Union, further emphasizes the need for adherence to Good Manufacturing Practices (GMP). The EU's Falsified Medicines Directive mandates rigorous compliance to ensure product integrity and patient safety. For Mylan, aligning with these standards is essential to maintain and expand its foothold in the European market.
About Mylan Laboratories Limited
Mylan Laboratories Limited exports 91 products worth $634.8M. Beyond Sitagliptin, top products include Tenofovir, Pantoprazole, Valsartan, Ritonavir, Trastuzumab. View the complete Mylan Laboratories Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Sitagliptin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Sitagliptin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Mylan Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 233 individual customs records matching Mylan Laboratories Limited exporting Sitagliptin, covering 128 formulations to 10 countries via 35 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 121+ countries, 575+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Sitagliptin Export Data from Mylan Laboratories Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Mylan Laboratories Limited's Sitagliptin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Mylan Laboratories Limited
Full Company Profile →
91 products · $634.8M total trade · 26 categories
Sitagliptin Stats
Company Overview
Top Products by Mylan Laboratories Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Mylan Laboratories Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Sitagliptin. For current shipment-level data, contact TransData Nexus.